NOCDURNA is the first and only FDA-approved sublingual tablet that treats NP

(nocturnal polyuria) in adults who awaken at least 2 times per night to void1

* Reference: 1. Weiss JP, van Kerrebroeck PEV, Klein BM, Nørgaard JP. Excessive nocturnal urine production is a major contributing factor to the etiology of nocturia. J Urol. 2011;186(4):1358-1363.

Nocdurna dissolves rapidly and starts working quickly1

Sublingual tablet dissolves
in seconds—without water1,2

NOCDURNA starts working
in minutes

Onset of antidiuretic action occurs within 30 minutes on average1


2.8 hours

The antidiuretic action of NOCDURNA lasts 6 hours after dosing (on average)

Nocdurna May Reduce Your Patients Nighttime Voids

Patients taking nocdurna wake up fewer times to void

The majority of patients had their nightly voids cut by at least 33%1*‡

In a study where nocturia patients averaged 3 nighttime bathroom visits1

78% Women

95% CI [1.36, 3.41] (N=118)

67% Men

95% CI [1.30, 3.14] (N=102)

NOCDURNA reduced mean number of nighttime voids by nearly half1



95% CI [-0.5, -0.1] (N=118)



95% CI [-0.6, -0.2] (N=102)

  1. Adjusted probability of achieving at least a 33% mean reduction from baseline in average number of nightly voids. 33% responder rate used to ensure a reasonable estimate of clinical benefit.
  2. Mean reduction of 1.5 voids in women and 1.3 voids in men relative from mean baselines of 2.9 in women and 3.0 in men.
  3. A 33% responder was defined as a subject with a decrease of at least 33% in the mean number of nocturnal voids compared to baseline.

NOCDURNA reduced and sometimes eliminated nighttime voids

Percent (%) of nights with at most 1 void1

Percent (%) of men and women with no voids1

Nights without voids measured 0% at baseline and increased to 19% at the end of 3 months.

Nocturnal Polyuria can coexist with OAB and BPH.

Concomitant use of anti-muscarinic medications, alpha-blockers, and alpha-reductaseinhibitors was permitted for patients on a stable dose prior to study entry.

Study Description

The efficacy of NOCDURNA was established in two 3-month, randomized, double-blind, placebo-controlled, multi-center trials in adults over 18 years of age. Study 1 included 237 female patients and Study 2 included 230 male patients. Women received NOCDURNA 27.7 mcg and men received NOCDURNA 55.3 mcg. The co-primary endpoints were the change in number of nighttime voids compared to baseline and the percentage of patients who achieved a 33% reduction from baseline in the mean number of nighttime voids.1

Reference: 1. NOCDURNA [package insert]. Parsippany, NJ: Ferring Pharmaceuticals Inc.
Reference: 2. Data on File: NOC002